Department of Pathology Duke University School of Medicine Durham NC.
Department of Radiation Oncology Duke University School of Medicine Durham NC.
J Am Heart Assoc. 2023 Mar 21;12(6):e028234. doi: 10.1161/JAHA.122.028234. Epub 2023 Mar 9.
Background We recently reported aberrant processing and localization of the precursor PNC (pro-N-cadherin) protein in failing heart tissues and detected elevated PNC products in the plasma of patients with heart failure. We hypothesize that PNC mislocalization and subsequent circulation is an early event in the pathogenesis of heart failure, and therefore circulating PNC is an early biomarker of heart failure. Methods and Results In collaboration with the Duke University Clinical and Translational Science Institute's MURDOCK (Measurement to Understand Reclassification of Disease of Cabarrus and Kannapolis) study, we queried enrolled individuals and sampled 2 matched cohorts: a cohort of individuals with no known heart failure at the time of serum collection and no heart failure development in the following 13 years (n=289, cohort A) and a matching cohort of enrolled individuals who had no known heart failure at the time of serum collection but subsequently developed heart failure within the following 13 years (n=307, cohort B). Serum PNC and NT-proBNP (N-terminal pro B-type natriuretic peptide) concentrations in each population were quantified by ELISA. We detected no significant difference in NT-proBNP rule-in or rule-out statistics between the 2 cohorts at baseline. In participants who developed heart failure, serum PNC is significantly elevated relative to those who did not report development of heart failure (<0.0001). Receiver operating characteristic analyses of PNC demonstrate diagnostic value for subclinical heart failure. Additionally, PNC has diagnostic potential when comparing participants with no reported heart failure risk factors from cohort A to at-risk participants from cohort B over the 13-year follow-up. Participants whose PNC levels measure >6 ng/mL have a 41% increased risk of all-cause mortality independent of age, body mass index, sex, NT-proBNP, blood pressure, previous heart attack, and coronary artery disease (=0.044, n=596). Conclusions These data suggest that PNC is an early marker of heart failure and has the potential to identify patients who would benefit from early therapeutic intervention.
背景 我们最近报道了前体 PNC(原 N-钙粘蛋白)蛋白在衰竭心脏组织中的异常加工和定位,并在心力衰竭患者的血浆中检测到升高的 PNC 产物。我们假设 PNC 定位错误和随后的循环是心力衰竭发病机制中的早期事件,因此循环 PNC 是心力衰竭的早期生物标志物。 方法和结果 与杜克大学临床和转化科学研究所的 MURDOCK(测量理解卡巴鲁斯和坎纳波利斯疾病的再分类)研究合作,我们查询了入组个体并采样了 2 个匹配队列:一个队列的个体在采集血清时没有已知的心力衰竭,并且在接下来的 13 年内没有心力衰竭发展(n=289,队列 A),以及一个匹配的队列,其中入组个体在采集血清时没有已知的心力衰竭,但在接下来的 13 年内随后发展为心力衰竭(n=307,队列 B)。通过 ELISA 定量检测每个群体的血清 PNC 和 NT-proBNP(N 末端 pro B 型利钠肽)浓度。我们在基线时未检测到 2 个队列之间 NT-proBNP 规则内或规则外统计数据的显著差异。在发生心力衰竭的参与者中,与未报告心力衰竭发展的参与者相比,血清 PNC 显著升高(<0.0001)。PNC 的接收者操作特征分析表明其对亚临床心力衰竭具有诊断价值。此外,当将来自队列 A 的无报告心力衰竭危险因素的参与者与来自队列 B 的有风险的参与者进行比较时,PNC 具有诊断潜力在 13 年的随访中。PNC 水平测量值>6ng/mL 的参与者的全因死亡率风险增加 41%,独立于年龄、体重指数、性别、NT-proBNP、血压、先前的心脏病发作和冠状动脉疾病(=0.044,n=596)。 结论 这些数据表明 PNC 是心力衰竭的早期标志物,具有识别可能受益于早期治疗干预的患者的潜力。